Mike Hennessy Jr.

The 1VQ papers advocate for the idea that certain post-approval changes should be streamlined and expedited.

While the cost of certain medicines are alarmingly high, they can be considered a bargain measured against a lifetime of traditional costs.

How can we fix the quality manufacturing issues that come with product shortages?

Systemic inefficiencies in the pharmaceutical industry undermine problem-solving efforts.

AI could provide solutions to critical manufacturing inefficiencies.

Spring has returned, and with it comes INTERPHEX.

Advances in pharmaceutical neuroscience present an opportunity for pharmaceutical companies to stay ahead of the curve.

Reducing US dependency on overseas pharma manufacturing may prove critical in navigating supply chain disruptions.

Busy is good for business.